N-terminal acetylation and C-terminal amidation are often treated as routine options on a peptide order form. They still change molecular mass, charge, chromatographic behavior and the set of plausible impurities. When qualifying an N-terminal acetylated C-terminal amidated peptide supplier, place both termini in the material definition and require analytical evidence that distinguishes them from free-terminal variants.

Write terminal chemistry into the sequence

Use an explicit notation such as Ac–sequence–NH2 and define whether the residue numbering includes any added linker or tag. Do not rely on a product name ending in “amide,” which may be copied inconsistently between quotation, label and COA.

If only one terminus is modified, state the other as free acid or free amine. This prevents the supplier from applying its catalogue default. Terminal configuration must remain identical across reference, control and scale-up lots.

C-terminal amidation begins with the synthesis route

In solid-phase peptide synthesis, an amide-generating resin commonly determines the C-terminal functionality. Incorrect resin selection or cleavage can produce a free-acid analogue or other terminal impurity. For difficult sequences, deletion products containing the same terminal amide may complicate purification.

Ask the manufacturer to document resin identity and crude LC-MS. The final chromatogram alone does not reveal whether a terminal variant coelutes with the target.

N-terminal acetylation needs completion evidence

Acetylation is usually performed after chain assembly, but incomplete reaction leaves free-amine peptide. Over-acetylation of unintended sites can occur if side-chain protection or processing is poorly controlled. The supplier should define the reagent, endpoint and washing steps.

The expected mass shift supports completion, while LC-MS peak review should look specifically for the unacetylated mass. If the two forms are not chromatographically resolved, an extracted-ion comparison can be more informative than UV area purity alone.

Intact mass is necessary, not the whole identity package

The correct complete mass confirms that the dominant ion is consistent with both terminal modifications. It may not rule out an isobaric sequence error. For long, modified or high-value peptides, tandem MS or peptide mapping can strengthen sequence evidence.

Check whether the reported theoretical mass is monoisotopic or average and whether the calculation includes the correct termini. Counterion is usually assessed separately and should not be inferred from the peptide ion spectrum.

Terminal changes affect solubility and comparison studies

Acetylation removes a positive N-terminal charge, while amidation removes the negative charge of a C-terminal carboxylate. The net effect depends on sequence and pH. A modified peptide may dissolve differently from its free-terminal control and can shift retention on reversed-phase HPLC.

Run solubility checks at the intended concentration and matrix. Avoid forcing both variants into an unsuitable solvent merely for procedural symmetry. If the project compares modified and unmodified forms, report each material’s counterion, content and water.

Purity does not equal delivered peptide amount

HPLC area percentage measures the relative chromatographic signal under one method. It does not subtract water, acetate, TFA or residual solvent. Request net peptide content when researchers need molar equivalence between terminal variants.

For multiple vials, define whether the supplier fills by gross material weight or peptide-equivalent content. Bulk purity can remain constant while vial delivery varies.

• Explicit Ac–sequence–NH2 specification.
• Crude and final HPLC/LC-MS data.
• Search for unacetylated and free-acid variants.
• Correct theoretical-mass calculation and sequence evidence.
• Peptide content, counterion, water and vial-fill basis.

Do acetylation and amidation always improve stability? No. They can reduce some terminal reactions or better represent a native fragment, but they may also change solubility and assay behavior. The modification should follow the experimental design, not a generic preference.

Send the exact sequence, terminal forms, purity, content basis, scale and comparison controls with the RFQ. A qualified supplier should return a specification that makes every terminus auditable from batch record through vial label.

Biotin is small compared with many fluorescent dyes, but its position and linker still affect peptide binding, solubility and access to streptavidin. A custom biotinylated peptide synthesis service should define the complete conjugate and prove that free biotin and unlabeled peptide have been controlled. “Biotinylated” alone is not a release specification.

Select a site that does not obstruct the assay

N-terminal biotinylation is straightforward when the native N-terminus is not required for binding. A lysine side chain can provide another attachment site, provided other amines are protected and the selected lysine is not part of the interaction motif. An added cysteine followed by selective conjugation is useful for some constructs but creates a different peptide.

State whether the label is direct or separated by an Ahx, PEG or other spacer. A linker can improve accessibility on streptavidin-coated surfaces, yet it also changes hydrophobicity, mass and effective distance from the peptide.

Lock the exact construct in the quotation

Write the biotin and linker into the controlled sequence notation. Specify termini, disulfides, salt form and any other modification. If both biotinylated and unlabeled controls are needed, require identical peptide sequence and terminal chemistry.

For competition assays, consider ordering the control and conjugate from the same synthesis campaign or at least under aligned specifications. Lot differences in salt and content can otherwise look like label effects.

Free biotin is an assay-active impurity

Residual free biotin can occupy streptavidin sites even at levels that appear minor by peptide-focused HPLC. The analytical method must detect it or use an orthogonal test. UV response differs between free biotin, peptide and conjugate, so area normalization at one wavelength may be misleading.

Ask how excess reagent is removed and how the final free-biotin limit is verified. Dialysis or desalting alone may be inadequate for a hydrophobic peptide or when recovery is poor.

Confirm identity and attachment position

LC-MS should show the complete conjugate mass and reveal relevant unlabeled or multi-labeled species. When several reactive residues exist, the expected mass does not prove correct position. Selective protection, tandem MS or peptide mapping may be needed.

Review the full spectrum, not only a typed mass result. Biotinylation can change charge-state distribution and chromatographic retention. The HPLC and MS data must correspond to the shipped lot.

Content and immobilization are separate questions

Gross lyophilized weight includes counterion, water and residual salts. Net peptide content or another quantitative assignment is necessary when surface loading or solution concentration matters. A high HPLC purity result is not a vial-content result.

The buyer should validate functional capture in the intended streptavidin format. Linker length, surface density and peptide orientation can alter apparent binding. Supplier QC confirms chemical material; it does not prove performance in every plate, bead or sensor system.

Packaging should minimize adsorption and moisture

Low microgram fills are vulnerable to static loss and adsorption. Request low-bind vials, sensible aliquots and a documented fill tolerance. If the product is delivered in solution, define solvent, concentration basis, homogeneity, preservative status and shipping temperature.

• Exact biotin site and linker identity.
• Limits for free biotin, unlabeled and multi-labeled peptide.
• HPLC method, integration and full LC-MS data.
• Position evidence when multiple sites are possible.
• Content basis, counterion, aliquots and storage.

Does every biotinylated peptide need a linker? No. The decision depends on whether direct attachment interferes with recognition or surface access. Provide the assay format, immobilization surface, target concentration and required controls before synthesis. A technically useful supplier will question an attachment site likely to compromise the measurement.

A phosphopeptide order is not fully defined by adding “phosphorylated” to the sequence. The supplier needs the modified residue, positional numbering, terminal groups, salt form and intended comparison materials. During a custom phosphorylated peptide synthesis service review, I also ask how the laboratory distinguishes the target from unphosphorylated, partially phosphorylated and positional-isomer impurities.

Specify every phosphorylation site

Mark phosphoserine, phosphothreonine or phosphotyrosine directly in the controlled sequence. For multiply phosphorylated targets, list every site rather than relying on a total phosphate count. A mono-phosphorylated product at the wrong residue can have the expected intact mass.

Include the protein numbering system only as supporting information. The manufacturing specification should use unambiguous peptide residue positions because isoforms and initiator-methionine conventions can shift biological numbering.

Decide which control peptides are required

Kinase, phosphatase, binding and antibody studies often need a matched non-phosphorylated peptide. Some projects also require a phosphomimetic sequence, although aspartate or glutamate does not reproduce every structural or charge property of phosphate. Order controls from the same documented sequence and terminal configuration.

For quantitative work, consider whether a stable-isotope-labeled phosphopeptide is needed. The heavy label, phosphate site and enrichment must be specified independently.

Synthesis chemistry changes with phosphate load

Protected phospho-amino-acid building blocks can be incorporated during solid-phase peptide synthesis, but coupling efficiency and deprotection behavior depend on residue, neighboring sequence and protection strategy. Multiple phosphates increase charge and can reduce retention on conventional reversed-phase purification.

Ask the supplier to inspect the crude profile for deletion products and incomplete phosphorylation. A clean final HPLC trace does not show whether purification removed most of the batch or whether the route is robust enough for repeat supply.

Control dephosphorylation and rearrangement

Harsh cleavage, prolonged basic exposure and some sample-preparation conditions can reduce phosphate recovery. The manufacturing record should define cleavage, neutralization, purification and drying conditions. During analytical handling, use clean containers and suitable solvents; contaminating phosphatases are a practical risk in biological workflows, though they are not normally part of chemical manufacture.

Storage claims should fit the exact product. Hygroscopic salts, repeated freeze-thaw and poorly controlled solution pH can change recovery even if the covalent phosphate remains intact.

LC-MS must support site identity

Intact LC-MS can confirm the expected mass increment, but it cannot always localize a phosphate. Tandem MS should provide fragments on both sides of the modified residue where site certainty matters. Neutral loss can dominate some fragmentation spectra, so the laboratory may need optimized collision conditions or an alternative fragmentation mode.

Request annotated spectra and a coverage map. If adjacent serine or threonine residues prevent confident localization, the report should say so rather than assign a site from the order form.

Chromatography needs a suitable method

Phosphorylation changes charge and retention. The parent and phosphopeptide may separate well under one gradient and overlap under another. Review the stationary phase, mobile phase, gradient, wavelength, injection amount and integration table. For multi-phosphorylated material, ion-pairing conditions can strongly influence peak shape.

HPLC area purity is not net content. Counterions, water and residual salts can represent substantial gross weight. Request peptide-content data when the study depends on molar concentration.

• Controlled sequence with residue-level phosphate sites.
• Matched unmodified controls and terminal configuration.
• Final and crude HPLC/LC-MS evidence.
• MS/MS localization where the application requires it.
• Content basis, counterion, water, fill and storage.

What purity is appropriate for a phosphopeptide? It depends on whether the material is used for screening, antibody work or quantitative calibration. A higher area percentage cannot compensate for uncertain site localization. Send the assay, required controls, scale and acceptance criteria with the RFQ so the supplier can design the route and QC package around the actual experiment.